A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Academic Article uri icon

Overview

abstract

  • The aim of this study was to investigate the anti-tumour activity of temozolomide in patients with malignant pleural mesothelioma. 27 chemotherapy-naïve patients with histologically-proven malignant mesothelioma were treated with temozolomide 200 mg/m2/day, given orally on days 1-5 of each 28-day cycle. Therapy continued up to 10 cycles unless disease progression or excessive toxicity mandated discontinuation. Toxicity, symptom improvement and pain intensity were regularly assessed. With a median relative dose intensity of 97%, toxicity was moderate with grade 3 or more nausea, vomiting, thrombocytopenia, leucocytopenia, neutropenia, febrile leucocytopenia, arthralgia, infection and fever with infection occurring in 13, 13, 10, 3, 7 and 3% of patients for the remaining events, respectively. Overall, 1 objective response was observed (response rate 4%, 95% Confidence Interval (CI): 0.1-19). Median survival was 8.2 months. Symptom assessment showed no improvement and an increase of pain was observed during the study. Thus, oral temozolomide is an inactive agent in malignant mesothelioma.

publication date

  • April 1, 2002

Research

keywords

  • Antineoplastic Agents, Alkylating
  • Dacarbazine
  • Mesothelioma
  • Pleural Neoplasms

Identity

Scopus Document Identifier

  • 0036203913

Digital Object Identifier (DOI)

  • 10.1016/s0959-8049(01)00428-2

PubMed ID

  • 11937311

Additional Document Info

volume

  • 38

issue

  • 6